Erratum: Soluble fms-Like Tyrosine Kinase-1 and Endothelial Adhesion Molecules (Intercellular Cell Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1) as Predictive Markers for Blood Pressure Reduction After Renal Sympathetic Denervation (Hypertension (2014) 63 (984–990) DOI: 10.1161/HYPERTENSIONAHA.113.02266);Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (Intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation

Hypertension

Volumn 63, Issue 5, 2014, Pages 984-990

  Dörr, Oliver ^a   Liebetrau, Christoph ^a   Möllmann, Helge ^b   Gaede, Luise ^b   Troidl, Christian ^b   Rixe, Johannes ^a   Hamm, Christian ^b   Nef, Holger ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Kerckhoff Heart and Thorax Center   (Germany)

Author keywords

Biological markers; Hypertension

Indexed keywords

ANGIOGENIC FACTOR; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; CREATININE; INTERCELLULAR ADHESION MOLECULE 1; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENAL SYMPATHETIC DENERVATION; RESISTANT HYPERTENSION; SYMPATHETIC FUNCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; HYPERTENSION;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD PRESSURE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; ROC CURVE; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TIME FACTORS; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84902288376     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYP.0000000000000235     Document Type: Erratum

References (35)

1. Task force for the management of arterial hypertension of the European Society of Cardiology. Guidelines for the management of arterial hypertension. Eur Heart J. 2007; 28: 1462-1536.
2. Singh RB, Bajaj S, Niaz M.A., Rastogi SS, Moshiri M. Prevalence of type 2 diabetes mellitus and risk of hypertension and coronary artery disease in rural and urban population with low rates of obesity. Int J Cardiol. 1998; 66: 65-72. (Pubitemid 28451680)
3. The National High Blood Pressure Education Program Working Group. Report on hypertension in diabetes. Hypertension. 1994; 23: 145-158.
4. Ghaffar A, Reddy KS, Singhi M. Burden of non-communicable diseases in South Asia. BMJ. 2004; 328: 807-810. (Pubitemid 38446379)
5. Mulvihill NT, Foley JB, Crean P, Walsh M. Prediction of cardiovascular risk using soluble cell adhesion molecules. Eur Heart J. 2002; 23: 1569-1574. (Pubitemid 35221560)
6. Muller WA, Weigl SA, Deng X, Phillips DM PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med. 1993; 178: 449-460. (Pubitemid 23218193)
7. Hood JD, Meininger CJ, Ziche M, Granger HJ VEGF upregulates eNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998; 274: 1054-1058.
8. Neagoe PE, Lemieux C, Sirois MG Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem. 2005; 280: 9904-9912. (Pubitemid 40395838)
9. Bates DO, Hillman NJ, Williams B, Neal C.R., Pocock TM Regulation of microvascular permeability by vascular endothelial growth factors. J Anat. 2002; 200: 581-597. (Pubitemid 34823050)
10. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18: 4-25. (Pubitemid 27076453)
11. Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GY. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol. 2001; 87: 805-807, A9. (Pubitemid 32209107)
12. Burt LE, Forbes MS, Thornhill B.A., Kiley SC, Chevalier RL Renal vascular endothelial growth factor in neonatal obstructive nephropathy. I. Endogenous VEGF. Am J Physiol Renal Physiol. 2007; 292:F158-F167. (Pubitemid 46105255)
13. Shimojo N, Jesmin S, Zaedi S., Otsuki T, Maeda S, Yamaguchi N., Aonuma K, Hattori Y, Miyauchi T. Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol. 2007; 293:H474-H481. (Pubitemid 47105105)
14. Tischer E, Mitchell R, Hartman T., Silva M, Gospodarowicz D, Fiddes J.C., Abraham JA. The human gene for vascular endothelial growth factor. J Biol Chem. 1991: 266; 11947-11954.
15. Clark DW. Effects of immunosympathectomy on development of high blood pressure in genetically hypertensive rats. Circ Res. 1971; 28: 330-336.
16. Lee RM, Triggle CR, Cheung D.W., Coughlin MD Structural and functional consequence of neonatal sympathectomy on the blood vessels of spontaneously hypertensive rats. Hypertension. 1987; 10: 328-338. (Pubitemid 17121907)
17. Calhoun DA, Jones D, Textor S., Goff DC, Murphy TP, Toto RD, White A, Cushman W.C., White W., Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008; 117:e510-e526.
18. Lloyd-Jones D., Adams R, Carnethon M. Heart disease and stroke sta-tistics-2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation. 2009; 119: 480-86.
19. Kearney PM, Whelton M, Reynolds K., Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365: 217-223. (Pubitemid 40138015)
20. Kopp UC, Cicha MZ, Smith L.A., Mulder J., Hökfelt T. Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol. 2007; 293:R1561-R1572. (Pubitemid 47535774)
21. Hausberg M, Kosch M, Harmelink P., Barenbrock M, Hohage H, Kisters K., Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002; 106: 1974-1979. (Pubitemid 35176304)
22. Krum H, Schlaich M, Whitbourn R., Sobotka PA, Sadowski J, Bartus K, Kapelak B., Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373: 1275-1281.
23. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010; 376: 1903-1909.
24. Blann AD, Tse W, Maxwell S.J., Waite MA Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens. 1995; 13: 1674-1678.
25. Levine RJ, Maynard SE, Qian C, Lim K.H., England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs B.P., Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of pre-eclampsia. N Engl J Med. 2004; 350: 672-683. (Pubitemid 38364626)
26. Blann AD, Tse W, Maxwell S.J., Waite MA Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens. 1995; 13: 1674-1678.
27. DeSouza CA, Dengel DR, Macko R.F., Cox K., Seals DR Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens. 1997; 10(12 pt 1): 1335-1341. (Pubitemid 28078736)
28. Lip GY, Blann AD, Zarifis J, Beevers M., Lip PL, Beevers DG Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report. J Hypertens. 1994; 12: 925-928.
29. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001; 103: 491-495. (Pubitemid 32116231)
30. Nadar SK, Blann AD, Kamath S, Beevers D.G., Lip GY Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Int J Cardiol. 2004: 94: 293-300.
31. Madej A, Okopien B, Kowalski J., Haberka M, Herman ZS Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension. Int J Cardiol. 2005; 98: 39-44.
32. Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GY. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol. 2001; 87: 805-807, A9. (Pubitemid 32209107)
33. Mahfoud F, Ukena C, Schmieder R.E., et al Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013; 128: 132-140.
34. Persu A, Jin Y, Azizi M., et al Blood pressure changes after renal dener-vation at 10 European expert centers. J Hum Hypertens. September 26, 2013. doi:10.1038/jhh.2013.88.
35. Schlaich MP, Sobotka PA, Krum H, Lambert E., Esler MD Renal sympatheticnerve ablation for uncontrolled hypertension. N Engl J Med. 2009; 361: 932-934.